Next Article in Journal
Highly Active Thermophilic L-Asparaginase from Melioribacter roseus Represents a Novel Large Group of Type II Bacterial L-Asparaginases from Chlorobi-Ignavibacteriae-Bacteroidetes Clade
Previous Article in Journal
Management of Osteoporosis in Men: A Narrative Review
Previous Article in Special Issue
The Gut-Brain Axis in Inflammatory Bowel Disease—Current and Future Perspectives
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 22
Issue 24
10.3390/ijms222413642
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Mucins Dynamics in Physiological and Pathological Conditions

by
Hassan Melhem
1,*,
Daniel Regan-Komito
2 and
Jan Hendrik Niess
1,3,*
1
Department of Biomedicine, University of Basel, 4031 Basel, Switzerland
2
Roche Pharma Research & Early Development, Immunology, Infectious Diseases and Ophthalmology (I2O), Roche Innovation Center, 4031 Basel, Switzerland
3
University Center for Gastrointestinal and Liver Diseases, St. Clara Hospital and University Hospital of Basel, 4031 Basel, Switzerland
*
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2021, 22(24), 13642; https://doi.org/10.3390/ijms222413642
Submission received: 30 October 2021 / Revised: 10 December 2021 / Accepted: 16 December 2021 / Published: 20 December 2021
(This article belongs to the Special Issue Changing Paradigms in Inflammatory Bowel Diseases)
Browse Figures
Versions Notes

Abstract

:
Maintaining intestinal health requires clear segregation between epithelial cells and luminal microbes. The intestinal mucus layer, produced by goblet cells (GCs), is a key element in maintaining the functional protection of the epithelium. The importance of the gut mucus barrier is highlighted in mice lacking Muc2, the major form of secreted mucins. These mice show closer bacterial residence to epithelial cells, develop spontaneous colitis and became moribund when infected with the attaching and effacing pathogen, Citrobacter rodentium. Furthermore, numerous observations have associated GCs and mucus layer dysfunction to the pathogenesis of inflammatory bowel disease (IBD). However, the molecular mechanisms that regulate the physiology of GCs and the mucus layer remain obscured. In this review, we consider novel findings describing divergent functionality and expression profiles of GCs subtypes within intestinal crypts. We also discuss internal (host) and external (diets and bacteria) factors that modulate different aspects of the mucus layer as well as the contribution of an altered mucus barrier to the onset of IBD.

1. Introduction

The epithelial surface of our gastrointestinal tract (GI) is formed by a single layer of active cells that separates immune cells from an enormous source of stimuli. These include gut commensal bacteria, pathogens and food antigens [1]. Under normal conditions, immune reactions against the listed stimuli are well controlled, thanks to the mucus barrier. The barrier is formed by mucins, a large glycoprotein heavily decorated with O-linked glycans. The O-glycosylation process is of importance for mucin protection, as it creates a glycan coat that hides the protein core from protease degradation [2]. Mucins can be classified into transmembrane and gel-forming mucins [3]. It is important to note that Muc2 is the major form of secreted mucins [4]. Differences in terms of thickness and type of mucins exist within the different segments of the GI tract. Numerous factors, such as cytokines, dietary, bacteria-derived factors and toxins, have been shown to modulate mucin turnover, including production, secretion and degradation processes, thus affecting the mucus barrier [5,6].
This review is divided in three subparts in which we will detail characteristics of the different GCs subpopulation, key factors regulating the biology of the mucus barrier and its implication in gut disorders.

2. Heterogeneous Population

Within the intestinal epithelium reside GCs, the primary secretory cells of the GI tract. They are recognized by their apical accumulation of mucin containing granules (Figure 1A) and they display positive staining to PAS Alcian Blue stain (Figure 1B). The production and secretion of mucins is the responsibility of GCs. Similarly to other intestinal epithelial subtypes, GCs derive by mitosis from Lgr5+ intestinal stem cells residing at the base of the crypt [7]. Transcriptional analysis has identified factors involved in GCs maturation and differentiation. For example, inhibition of the Notch pathway and its major effector protein Hes1 robustly drives progenitor lineage cells into differentiated GCs [8] (Figure 1C). Conversely, upregulation of Math1 (also known as Hath1) and Gfi1 promoted differentiation of progenitor cells into secretory cell lineages, including GCs. Further studies on the genetic regulation of GC maturation have identified Spdef as a key factor needed for proper GC maturation and function [9]. Classically, GCs are viewed as a homogenous secretory cell type. In light of new evidence, this view has changed, as a recent study indicates functional and gene expression profile differences of GCs in spatially distinct regions within the crypt. Transcriptional dysregulation of GCs marked by downregulation of WFDC2, an antiprotease molecule that preserves the integrity of tight junctions and prevents invasion by commensal bacteria and mucosal inflammation, was observed in IBD patients [10]. A recent study further demonstrated the diversity of GCs by identifying a subpopulation located at the colonic luminal, named intercrypt GCs (icGCs) [11]. Compared to the crypt-resident GCs, icGCs were characterized by a unique gene expression pattern and a different organization of mucus production with distinct properties [11]. Live tissue imaging revealed that icGCs mucus filled the regions between the mucus secreted by crypt-resident GCs and was impenetrable to bacteria-sized 1 μm beads [11]. The same study indicated fewer icGCs and disturbed mucus organization in biopsies from ulcerative colitis (UC) patients (both in active disease or in remission) [11]. In addition, a population of GCs, called goblet cell-associated antigen passages (GAPs), was shown to sense luminal antigens and deliver them to CD103+CD11c+ lamina propria dendritic cells [12]. These intraluminal antigens are subjected to mucus filtering whereby high molecular weight soluble antigens are excluded [12,13]. The preferential delivery to CD103+CD11c+ dendritic cells, which are suggested to induce tolerance to food antigens by interacting with regulatory T cells, implies an essential role of GAPs in intestinal immune homeostasis. Lastly, it has been shown that colon mucus includes a major layer produced by GCs of the proximal colon, which encapsulates fecal containing-bacteria, and a minor layer derived from GCs of the distal colon [14]. Together, these findings highly suggest that GCs subtypes within the intestinal epithelium are heterogenous.

3. Mucins

3.1. Classifications, Structural Organization and Differences within the GI Tract

Mucins are the major product of GCs. They form a biological gel covering the epithelium surface and are vital for maintaining gut homeostasis. This requires continuous secretion, estimated to be 10 L per day [15]. Water (90–95%), electrolytes, lipids (1–2%) and various proteins represent the key mucin elements [16,17]. To date, 21 different mucin genes have been identified [3]. Common to each mucin is a protein core characterized by a high frequency of the amino acids residues proline (Pro), threonine (Thr) and serine (Ser), named the PTS-rich domain [18]. Up to 80% of the mucin mass is made of O-glycans, indicating that the glycosylation represents a vital process for both protection and performance of mucin [6,19]. The mucins can be classified into two groups: transmembrane mucins and gel-forming mucins [3] (Table 1).
The transmembrane mucins include MUC1/3/4/12/13/15/17/20 and 21 [2,4]. Their main function is to protect enterocytes by covering their apical surface [20]. They vary in length with MUC16 being the longest and MUC13 being the shortest [3]. In the GI tract, transmembrane mucins are continually expressed with the exception for MUC1 and MUC16 [3].
The gel-forming mucins form the skeleton of the mucus system. They include MUC2/5AC/5B and 6, with MUC2 being the best characterized secreted mucin [3]. MUC5AC covers the stomach epithelial surface [21]. However, the mechanisms protecting MUC5AC from hydrochloric acid and pepsinogen in the stomach remain unknown. MUC6 is expressed by Brunner’s glands and duodenum [4].
Along the GI tract, GCs and the mucus layer differ in terms of distribution, composition, organization, thickness and expression profile (Figure 2). The percentage of GCs in the intestinal epithelium increases gradually from the duodenum (4%) toward the distal colon (16%) [22]. This abundance positively correlates with the distribution of intestinal flora distribution [5]. The small intestine displays a single nonattached mucus layer that is easily removed [23]. It is built around the mucin MUC2, which after secretion, remains anchored to GCs and requires the intervention of the protease meprinβ for its detachment [24]. The mucus layer in the small intestine is penetrable to bacteria; however, antibacterial mediators particularly those of Paneth cells fortify the mucus layer and keep away the bacteria from epithelial cells, except for segmented filamentous bacteria at the tip of the villi [6,25,26,27]. The enterocytes of the small intestine display the thickest mucus layer. In mice, an estimation of 500 μm, 250 μm, 200 μm and 150 μm thickness was shown for the duodenum, jejunum, ileum and colon, respectively [23].
Unlike the small intestine, the mucus layer of the large intestine consists of two layers: an outer and an inner layer. The outer layer is a nonattached, less dense layer and serves as a habitat for colonic bacteria. To the contrary, the inner layer is attached, continuously filled by the mucin MUC2 and almost free of bacteria [19,28].

3.2. Mucins and Intestinal Microbiota: Mutual Interaction

Mucin glycans serve as binding sites [29] as well as energy sources [30] required for the replication of microorganisms [6]. Through the activity of glycosidase enzymes, bacteria have the ability to degrade glycan [31]. These enzymes represent up to 40% of the bacterial genomes. Together, these observations clearly demonstrate a mutualistic interaction between the host and the gut microflora. On the other hand, the presence of intestinal microbiota is essential for GCs and the mucus layer. An elegant study [32] has investigated the physiology of the mucus barrier in two different wild-type C57BL/6 mouse colonies housed and bred separately in the same specific pathogen-free mouse facility. Surprisingly, one of the colonies had an impenetrable mucus layer whereas the other colony had an inner mucus layer penetrable to bacteria and beads [32]. This phenotype was confirmed by colonizing germ-free mice with the flora from the two colonies. Interestingly, a 16S rRNA gene sequencing analysis indicated different bacterial compositions specific to each colony [32]. The germ-free inner mucus layer is penetrable by bacteria-sized beads and thinner compared to those of conventionally raised mice [33]. As mentioned above, the protease meprinβ, required for the release of mucus in the small intestine, seems to be controlled by the presence of bacteria, as germ free mice and and meprin β-deficient mice have an attached mucus layer [24]. Moreover, several bacterial metabolites are increasingly recognized for their effects on goblet cells. In particular, short chain fatty acids (SCFAs; mainly butyrate, propionate and acetate) stimulate mucins and gene expression of other GCs products, such as TFF3 [34,35,36,37]. Similarly, the tryptophan metabolite indoleacrylic acid produced by the commensal Peptostreptococcus species and the aryl hydrocarbon receptor (AhR) were shown to induce goblet cell differentiation and function in mice [38,39]. Furthermore, SCFAs increase MUC2 expression via AP-1 and acetylation/methylation of histones at the MUC2 promoter [40]. The signaling of SCFAs by G-protein-coupled receptors (GPRs) promotes goblet cell function [41].

4. Modulators of Goblet Cells and the Mucus Layer

A large number of internal (host) and external (pathogens, diet and xenobiotics) stimuli have been reported to regulate the physiology of goblet cells, but also all steps of the mucin lifecycle, rendering this regulation very complex. Thus, uncovering the molecular mechanisms modulating goblet cell functions and mucin turnover is of special importance.

4.1. Immunomodulation

Over the years, a series of studies showed that mucin expression/secretion is tightly controlled by bioactive cytokines. These cytokines are secreted by immune and non-immune activated cells. They are mainly classified into either type 1 (Th1; including IL-2, IL-12 and IFN-γ) or type 2 (Th2; including IL-4, IL-9, IL-10 and IL-13) cytokines. In general, the transcriptional regulation of mucins is mediated by the induction of signaling pathways, such as JAK/STAT, SAPK/JNK or MAPK, which in turn activate the transcription factor NF-κB [42,43]. A specific binding site of NF-κB has been described on the mucin promotor. In Figure 3, we summarize the mucin expression in response to cytokines.
Many Th1 cytokines, notably IFN-γ, TNF-α and IL-1β, appear to regulate the production/exocytosis of both transmembrane and gel-forming mucins. One study reported that IFN-γ positively modulates mucin exocytosis in the human colonic goblet cell line Cl.16E without altering mucin gene expression [44]. Another study reported that activation of IFN-γ receptor resulted in an elevated MUC1 expression level via the JAK/STAT pathway [45]. Similarly, TNF-α upregulated the expression of MUC2 and MUC5B but had no effect on the expression of MUC5AC and MUC6 in LS180 cells [46]. These findings were confirmed at the protein level [46]. The authors of this study also demonstrated that IL-1β stimulated the mRNA expression of MUC2 and MUC5A [46].
Furthermore, type 2 cytokines seem to strongly regulate mucin gene expression. Indeed, IL-4 and IL-13 upregulated MUC2 and MUC5AC transcription by activating either the STAT6 or NF-κB pathways [47,48]. Moreover, in HT-29CL.16E and HT29 cell lines, these cytokines also upregulated the expression level of other goblet cell products, such as TFF3 in a STAT-6-dependent manner [49]. In contrast, IL-4 and IL-13 displayed a negative regulation of mucin genes in non-colonic cell lines. For example, in nasal epithelial cells, IL-13 suppresses MUC5AC gene expression and mucin secretion [50]. In addition, the stimulation of human bronchial epithelial cells with IL-4 inhibited mucus secretion and downregulated the gene expression level of MUC5AC and MUC5B [51]. Another type 2 cytokine, IL-9, also induces expression of MUC2 and MUC5AC in human primary lung cultures and in the human NCI-H292 cell line [52]. Similar results were observed in C57BL/6J mice after IL-9 intratracheal instillation [52]. Furthermore, treatment of mice with anti-IL-10 resulted in the accumulation of unfolded MUC2 [53]. This effect was reversed by stimulating LS174T cells with IL-10 following pre-treatment with an ER stress inducer, namely, tunicamycin [53]. Incubation of LS180 cells with IL-6 induced the expression of MUC2, MUC5B and MUC6 [46]. Lastly, an IL-22 treatment ameliorated intestinal inflammation by enhancing mucus production in a STAT3-dependant manner [54].
Beside cytokines, numerous studies showed that deficiency of several inflammasome proteins, including NLRP6, ASC, and caspase-1, mediated autophagy impairment in GCs that resulted in altered mucin granule exocytosis, leading to impaired colonic host-microbial interactions [41]. In contrast, it has been demonstrated that colonic inner mucus layer formation and function are independent of NLRP6 inflammasome activity [55]. A variety of studies concluded a contradictory role of the inflammasome substrate cytokine IL-18. On one hand, IL-18 was shown to regulate the production of anti-microbial peptides and shape the homeostasis of the microbiome, thereby avoiding the outgrowth of colitogenic microbiota [56]. On the other hand, Nowarski et al., demonstrated that epithelial IL-18 drives goblet cell depletion and prevents functional goblet cell maturation [57]. A more recent study claimed that IL-18 produced by the enteric nervous system is essential for protection against bacterial infection via goblet cell antimicrobial peptide production, indicating a divergent role of IL-18 in colitis [58]. Lastly, mice lacking the bacterial sensor NOD2 displayed a decreased Muc2 expression level and a higher abnormal fused granule [59].

4.2. Dietary Modulation

Nutrition impacts mucus layer characteristics. This is predominantly addressed by feeding mice with specific regimes recapitulating human diets. Non-digestible fibers and polysaccharides are generally considered as energy sources for gut bacteria. In the absence of fibers, bacteria use mucus glycan metabolism to fulfill its energy demands, suggesting an association between diet and mucins [60]. Accordingly, low-fiber diet is associated with a thinner mucus layer [61,62,63]. In a gnotobiotic mouse model, dietary fiber deficiency induced damage in the mucus layer, decreased the production of MUC2 and promoted the enrichment of mucin-degrading bacteria [64]. Together, these observations resulted in enhanced susceptibility to Citrobacter rodentium infection [64]. On the other hand, diets enriched in inulin fiber or probiotic bifidobacterial were shown to protect mucus deterioration [65]. Furthermore, the combination of fructooligosaccharide and resistant starch upregulated MUC2 expression in rats [66].
Western diets rich in saturated fats have been reported to cause a marked change in the functionality of the mucus barrier. In this context, reduction in fucosylated and sulfated residuals in the goblet cells of villi was observed in mice fed with a high fat diet during 25 weeks [67]. Another study revealed that a prolonged high fat diet leads to ER and oxidative stress in goblet cells reducing the production and secretion of mucins needed for a protective barrier [68]. This phenotype was more enhanced in Winnie mice [68]. Similarly, mice fed with high fat/high sugar displayed a thinner mucus layer and increased intestinal permeability and changes in microbial communities [69]. These modifications enhanced the ability of adherent-invasive E. coli to colonize the gut mucosa [69]. In line with these observations, a more recent study demonstrated that a high fat/high sugar diet created an inflammatory environment in the gut characterized by an overrepresentation of pro-inflammatory bacteria, such as Proteobacteria, and a significant reduction of SCFA concentrations [70]. Furthermore, food additives, including emulsifiers, are classified as agents that disrupt the mucus-bacterial interactions. Confocal microscopy analysis of mice fed with either carboxymethylcellulose or polysorbate-80 via drinking water indicated a closer bacterial residence to the epithelium and increased levels of mucolytic bacteria, including Ruminococcus gnavus [71]. These findings correlated with reduced mucus thickness without changes in MUC2 expression [71]. Moreover, the administration of maltodextrin promoted an activated ER stress in goblet cells and reduced MUC2 expression [72]. No significant change in mucosa-associated bacteria was observed in these mice [72].
Beside dietary fiber and the Western diet, a high-protein diet is associated with hyperplasic goblet cells and reduced mucosal myeloperoxidase activity [73]. A long-term high protein diet was shown to alter microbial composition in a rat model [74,75]. However, a short-term high protein diet had no significant effects on the gut microbiota composition [76].

5. Other Modulators

Delivery of granule mucin contents can be also induced by intracellular Ca2+ mobilizing agents. Among them, acetylcholine has been shown to stimulate mucin secretion in the small and large intestine. In addition, PGE2 promoted mucin secretion in a cAMP-dependent manner. Phorbol 12-myristate 13-acetate (PMA) also stimulated mucin release, implicating a responsive protein-kinase C-dependent pathway.
Xenobiotics, including aflatoxin M1, ochratoxin A, trichothecene mycotoxins toxin and deoxynivalenol, have been shown to affect goblet cell functions and MUC2 expression. This transcriptional inhibition was mediated by different pathways, including IRE1/XBP1, protein kinase R and mitogen-activated protein kinase p38 or mitochondrial dysfunction.

6. Bacterial Strategies for Overcoming the Mucus Layer

The continuity of the mucus layer is vital for intestinal homeostasis, as it forms the frontline defense of the gastrointestinal tract against bacterial infections [29]. Hence, bacteria need to contend with this barrier in order to access the epithelium. To this end, pathogens exploit several mechanisms allowing them to reach the epithelium in order to replicate and colonize.
Bacterial-derived products regulating mucin production and secretion:

6.1. Mucus Secretion

Induction. Several microbial products have been shown to regulate mucin transcription (Table 2). Among them, Gram-negative bacterial flagellin A binds to the surface receptor Asialo-GM1, resulting in ATP release [77]. This induces mucin transcription mediated by the phospholipase C/Ras pathway [77]. Similarly, lipopolysaccharide (LPS) form Gram-negative Pseudomonas aeruginosa and E. coli were described to upregulate MUC2, MUC5AC and MUC5B expression through the activation of the Ras-mitogen-activated protein kinase (MAPK)-mediated NF-κB activation pathway [78,79]. A number of bacterial species have been found to modulate GCs functions. Of these species, Bifidobacterium dentium [80] Ruminococcus gnavus [81] and Lactobacillus rhamnosus [82] regulate both mucin production and other mucosal defense factors produced by goblet cells, such as TFF3 and RELM-B. Furthermore, supplementation of the probiotics Lactobacillus casei GG, the cocktail VSL#3 and Lactobacillus acidophilus induced MUC2 mucin gene expression in Caco-2 and HT29 cell lines [83,84]. In agreement with this, Gram-positive lipoteichoic acid (LTA), a component of the cell wall, induced MUC2 mRNA expression in the human epithelial cell line HM3 by binding to the platelet-activating factor receptor [85].
Inhibition. Some pathogens opt for downregulating mucin production as a strategy to disrupt the mucus barrier integrity and promote their survival. Particularly, Helicobacter pylori and Clostridium difficile infections are closely associated with disrupted mucin synthesis and loss of mucus coat continuity. In this context, immunohistochemistry and in situ hybridization analysis on tissue biopsies of H. Pylori-infected patients indicated a significant decrease in MUC5AC expression level [86]. Furthermore, a 20% decrease in mucus thickness and 18% reduction in the gel-forming polymeric mucin content of mucus were observed in H. pylori positive subjects [87]. Exposure of gastric mucosal cells to H. Pylori LPS led to disrupted mucin synthesis and enhanced apoptosis [88]. These observations involved the ERK and p38 mitogen-activated protein kinase pathways [88]. In vitro studies revealed that MUC5AC and MUC1 synthesis was inhibited when KATOIII cells were incubated with H. Pylori [89]. Similarly, infection of the mucus-secreting human cell line HT29-CL.16E with H. Pylori resulted in inhibition of mucus secretion [90]. C. difficile is a common enteric pathogen and is known to provoke tissue damage and intestinal fluid secretion by the release of two toxins: A and B. Toxin A, produced by C. difficile, has been shown to induce a severe proinflammatory response characterized by excessive neutrophil recruitment [91]. In addition, toxin A stimulated the release of intracellular calcium and chemotactic response in human granulocytes [92]. Interestingly, toxin A inhibited the stimulation of mucin exocytosis in a dose-dependent manner without altering the baseline mucin exocytosis from HT29-CI.16E cells [93].

6.2. Degradation

Prior to infection, bacteria must traverse the mucus barrier. To this end, pathogens or commensal bacteria have evolved a wide repertoire of enzymes that cleave to glycoproteins.
Henderson and collaborators [94] identified and characterized a secreted protein named Pic (protein involved in intestinal colonization), which is encoded on the chromosome of both Enteroaggregative E. coli and Shigella flexeri and belongs to the subfamily of the serine protease autotransporters. The same study demonstrated a rapid proteolytic activity against bovine and murine mucus but not hog gastric mucin [94]. Surprisingly, another study claimed that Pic induces hypersecretion of mucus accompanied by an increase in the number of mucus-containing goblet cells [95]. Experimental Helicobacter suis infection disrupted mucin composition and glycosylation, decreasing the amount of H. suis-binding glycan structures in the pig gastric mucus niche [96]. Other pathogens use a different family of mucus-degrading proteins. Enterotoxigenic E. coli is strongly associated with severe diarrhea-mediated death in young children [97,98]. A key virulence element of this pathogen is the secretion of YghJ, a secreted and cell-surface lipoprotein. This enzyme belongs to the mucin-binding metalloprotease M60-like peptidase [99]. It promotes access of ETEC to epithelial cells by cleaving mucins of the small intestine, including MUC2 and MUC3 [99]. Of note, several studies have supported the use of this antigen as a broadly protective vaccine against the pathogenic E. coli species [100]. Shiga-toxin encoding the E. coli O113:H21 strain uses the subtilase cytotoxin for mucin degradation [101]. Bacterial proteases from V. cholerae, such as TagA [102] and extracellular chitinase (ChiA2) [103], have been described as mucin glycoproteins degraders. V. cholerae re-uses the release sugar from mucins in order to promote its survival in the intestine [103]. The pathogenicity of Entamoeba histolytica relies on the secretion of the cysteine protease 5 (EhCP5) [104]. Southern blot analysis indicated that the EhCP5 gene is missing in the non-pathogenic Entamoeba histolytica [104]. The cysteine proteases secreted from the Entamoeba histolytica disrupt the mucin polymeric network by specifically cleaving the C-terminal domain at two sites, whereas the N-terminal domain was resistant to proteolysis [105].
Overall, an altered O-glycosylation profile has been shown to have a disastrous impact on the functionality of the mucus barrier, as evidenced in different animal models. For instance, mice lacking the core 3β1, 3-N-acetylglucosaminyltransferase (C3GnT), the key enzyme for the synthesis of core 3-derived O-glycans, displayed a reduction in the Muc2 protein and increased permeability of the intestinal barrier [106]. Moreover, these mice were highly susceptible to DSS-induced colitis [106]. In addition, the loss of core 1-derived O-glycans in mice resulted in significantly reduced mucus thickness characterized by the loss of the “b1” layer of the mucus [14]. Hyposulfataemic NaS1 sulfate transporter null mice exhibited a worsened DSS-colitis score and developed systemic infections when challenged orally with Campylobacter jejuni [107].

7. Mucins and Gut Disease

IBD, including Crohn’s disease (CD) and UC, is a chronic, disabling inflammatory condition of the gastrointestinal tract [108]. The peak of these disorders occurs during adolescence and early childhood [109]. The available therapeutic options for IBD are still unsatisfactory, which places a large burden on the health system. Thus, the development of new therapeutic strategies in the pathogenesis of IBD has become indispensable. One unique hallmark of IBD is an altered mucus barrier or of mucin production [110] (Figure 4). In support of this, several animal models carrying a disrupted barrier integrity displayed IBD-like syndromes [111,112]. An early meta-analysis of three combined genome-wide association studies has identified the MUC19 gene as a risk locus for IBD [113]. In CD, the existing evidence shows a significant discrepancy between the disease, GCs and mucus layer. Pullan and coworkers observed more mucus in CD patients [114]. Nonetheless, a more recent study indicated that the mucus layer and the level of GC stored mucin in CD patients were comparable to healthy controls [115]. In contrast, dysregulated MUC5AC, MUC5B and MUC7 gene expression was reported in CD patients [116]. Furthermore, MUC1 mRNA expression was significantly decreased in the involved ileal mucosa of CD patients when compared to the healthy mucosa [117]. An altered MUC2 structure was observed in CD patients, as indicated by shorter oligosaccharide chain length (50% less), leading to loss of its viscoelastic properties [118].
On the other hand, the relation between UC and the mucin layer is well established. UC patients display a thinner mucus layer as a result of the reduced GCs number and impaired MUC2 production and secretion [114,115]. MUC9 and MUC20 gene expression was found to be significantly decreased in patients with active UC compared to both remission group and normal controls [119,120]. Aberrant mucin O-glycosylation characterized by shorter glycans was observed in UC patients and is associated with increased inflammation [121].
On the animal level, genetic loss of Muc2 leads to spontaneous colonic inflammation and higher susceptibility to DSS-induced colitis. In addition, Muc2-/- mice display excessive bacterial contact with epithelial cells [122]. In contrast, Muc4-/- mice demonstrated resistance to DSS-induce colitis, which can be explained by compensatory upregulation of the Muc2 and Muc3 level [123].
Another important candidate affecting the mucus barrier during IBD is the gut microbiota. The composition of intestinal microbiota is suspected to be a major risk factor for IBD pathogenesis. An increased abundance of mucin-degrading bacteria, including of the Ruminococcus family, has been reported in IBD patients [6,124].
Along with changes in gene expression, glycosylation or genetic polymorphisms associated with IBD, several cellular processes have been shown to be involved in the modulation of mucin secretion and to play a key role in the pathogenesis of IBD. GCs are one of the major epithelial cell types requiring robust endoplasmic reticulum (ER) function, which is due to the size, disulfide bonds and complexity of mucin transcripts, rendering them highly susceptible to inappropriate folding. During UC, GCs boost their mucin biosynthesis machinery to restore mucin expression, which can lead to an elevated level of misfolded mucin-induced ER stress. The use of Winnie and Eeyore strains demonstrated that misfolded Muc2 resulted in abnormal GCs morphology, GCs apoptosis and the development of chronic intestinal inflammation [111]. In addition, the authors of this study reported an accumulation of MUC2 precursor that correlated with elevated levels of ER stress in the GCs of UC patients [111]. Two ER resident proteins named anterior gradient homolog 2 (AGR2) [125] and fatty acid synthase (FAS) [126] were shown to modulate the intestinal mucus barrier. AGR2 forms disulfide bonds with MUC2 on the A cysteine residue of its thioredoxin-like domain, suggesting a direct role for AGR2 in mucin processing [125]. Moreover, mice lacking AGR2 were viable but were highly susceptible to colitis [125]. FAS is an insulin-responsive enzyme essential for de novo lipogenesis. Genetic deficiency of FAS inhibited the generation of palmitoylated MUC2, profoundly damaging the mucus barrier integrity [126]. This results in increased intestinal permeability, higher susceptibility to colitis and dysbiosis [126].
ER stress has been linked to various pathways, particularly autophagy. It is defined as a vital catabolic cellular process through which host (misfolded proteins and damaged organelles) and bacterial-derived products are degraded via lysosomes [127]. In IBD, autophagy has been classified as a key element modulating the IBD pathogenesis [128]. Genetic ablation of autophagy proteins, including Atg54, Atg14 and FIP200, altered GCs exocytosis [129]. This study clearly demonstrates the significant influence of autophagy in modulating goblet cell function; however, the upstream signaling pathway that induces autophagy remains unknown.

8. Conclusions

The historic view of the mucus barrier as a static lubricant needed for food and stool progression in the intestine has evolved in favor of a highly dynamic organ as well as offering important protection against luminal microbes. Furthermore, the mucus layer actively contributes to the host–microbiota mutualism. Mucus layer impairment including altered expression, secretion, degradation, glycosylation profile and viscosity have been implicated in the pathogenies of IBD. A mounting number of stimuli are being discovered that could positively or negatively modulate these parameters rendering the regulation of GCs and the mucus layer a very complex system. Therefore, it remains unclear whether a disrupted mucus layer during IBD is a cause or consequence of inflammation. Thus, uncovering signaling pathways related to mucin biology could potentially facilitate the development of relevant treatments for chronic gut inflammatory disorders.
In this regard, primary attention should be given to answer the following questions:
What are the major chaperones needed for a proper mucin folding?
How bacterial metabolites modulate mucins?
Whether a cooperative bacterial work is needed to degrade the mucins?
How to target therapeutically a specific variant of GCs?

Author Contributions

H.M. conceived the content and structure of the manuscript and drafted the figures. H.M., J.H.N. and D.R.-K. wrote the text. All authors have read and agreed to the published version of the manuscript.

Funding

The SNSF grant 310030_175548 to J.H.N supported this manuscript’s writing.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Acknowledgments

We thank members of the Gastroenterology Research Group, Department of Biomedicine for discussions.

Conflicts of Interest

D.R.-K. is an employee of Roche. H.M. and J.H.N. do not have any conflict of interests concerning this manuscript.

References

  1. Sender, R.; Fuchs, S.; Milo, R. Revised Estimates for the Number of Human and Bacteria Cells in the Body. PLoS Biol. 2016, 14, e1002533. [Google Scholar] [CrossRef] [Green Version]
  2. Hansson, G.C. Mucins and the Microbiome. Annu. Rev. Biochem. 2020, 89, 769–793. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Johansson, M.E.; Hansson, G.C. Immunological aspects of intestinal mucus and mucins. Nat. Rev. Immunol. 2016, 16, 639–649. [Google Scholar] [CrossRef]
  4. Tailford, L.E.; Crost, E.H.; Kavanaugh, D.; Juge, N. Mucin glycan foraging in the human gut microbiome. Front. Genet. 2015, 6, 81. [Google Scholar] [CrossRef] [Green Version]
  5. Kim, Y.S.; Ho, S.B. Intestinal goblet cells and mucins in health and disease: Recent insights and progress. Curr. Gastroenterol. Rep. 2010, 12, 319–330. [Google Scholar] [CrossRef] [Green Version]
  6. Etienne-Mesmin, L.; Chassaing, B.; Desvaux, M.; De Paepe, K.; Gresse, R.; Sauvaitre, T.; Forano, E.; de Wiele, T.V.; Schuller, S.; Juge, N.; et al. Experimental models to study intestinal microbes-mucus interactions in health and disease. FEMS Microbiol. Rev. 2019, 43, 457–489. [Google Scholar] [CrossRef] [Green Version]
  7. Barker, N. Adult intestinal stem cells: Critical driv.vers of epithelial homeostasis and regeneration. Nat. Rev. Mol. Cell Biol. 2014, 15, 19–33. [Google Scholar] [CrossRef] [Green Version]
  8. Clevers, H. The intestinal crypt, a prototype stem cell compartment. Cell 2013, 154, 274–284. [Google Scholar] [CrossRef] [Green Version]
  9. Gregorieff, A.; Stange, D.E.; Kujala, P.; Begthel, H.; van den Born, M.; Korving, J.; Peters, P.J.; Clevers, H. The ets-domain transcription factor Spdef promotes maturation of goblet and paneth cells in the intestinal epithelium. Gastroenterology 2009, 137, 1333–1345.e3. [Google Scholar] [CrossRef]
  10. Parikh, K.; Antanaviciute, A.; Fawkner-Corbett, D.; Jagielowicz, M.; Aulicino, A.; Lagerholm, C.; Davis, S.; Kinchen, J.; Chen, H.H.; Alham, N.K.; et al. Colonic epithelial cell diversity in health and inflammatory bowel disease. Nature 2019, 567, 49–55. [Google Scholar] [CrossRef]
  11. Nystrom, E.E.L.; Martinez-Abad, B.; Arike, L.; Birchenough, G.M.H.; Nonnecke, E.B.; Castillo, P.A.; Svensson, F.; Bevins, C.L.; Hansson, G.C.; Johansson, M.E.V. An intercrypt subpopulation of goblet cells is essential for colonic mucus barrier function. Science 2021, 372, eabb1590. [Google Scholar] [CrossRef] [PubMed]
  12. McDole, J.R.; Wheeler, L.W.; McDonald, K.G.; Wang, B.; Konjufca, V.; Knoop, K.A.; Newberry, R.D.; Miller, M.J. Goblet cells deliver luminal antigen to CD103+ dendritic cells in the small intestine. Nature 2012, 483, 345–349. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Shan, M.; Gentile, M.; Yeiser, J.R.; Walland, A.C.; Bornstein, V.U.; Chen, K.; He, B.; Cassis, L.; Bigas, A.; Cols, M.; et al. Mucus enhances gut homeostasis and oral tolerance by delivering immunoregulatory signals. Science 2013, 342, 447–453. [Google Scholar] [CrossRef] [Green Version]
  14. Bergstrom, K.; Shan, X.; Casero, D.; Batushansky, A.; Lagishetty, V.; Jacobs, J.P.; Hoover, C.; Kondo, Y.; Shao, B.; Gao, L.; et al. Proximal colon-derived O-glycosylated mucus encapsulates and modulates the microbiota. Science 2020, 370, 467–472. [Google Scholar] [CrossRef]
  15. Cone, R.A. Barrier properties of mucus. Adv. Drug Deliv. Rev. 2009, 61, 75–85. [Google Scholar] [CrossRef]
  16. Bansil, R.; Turner, B.S. The biology of mucus: Composition, synthesis and organization. Adv. Drug Deliv. Rev. 2018, 124, 3–15. [Google Scholar] [CrossRef]
  17. Paone, P.; Cani, P.D. Mucus barrier, mucins and gut microbiota: The expected slimy partners? Gut 2020, 69, 2232–2243. [Google Scholar] [CrossRef] [PubMed]
  18. Lang, T.; Hansson, G.C.; Samuelsson, T. Gel-forming mucins appeared early in metazoan evolution. Proc. Natl. Acad. Sci. USA 2007, 104, 16209–16214. [Google Scholar] [CrossRef] [Green Version]
  19. Johansson, M.E.; Larsson, J.M.; Hansson, G.C. The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions. Proc. Natl. Acad. Sci. USA 2011, 108 (Suppl. S1), 4659–4665. [Google Scholar] [CrossRef] [Green Version]
  20. Johansson, M.E.; Sjovall, H.; Hansson, G.C. The gastrointestinal mucus system in health and disease. Nat. Rev. Gastroenterol. Hepatol. 2013, 10, 352–361. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  21. Hasnain, S.Z.; Gallagher, A.L.; Grencis, R.K.; Thornton, D.J. A new role for mucins in immunity: Insights from gastrointestinal nematode infection. Int. J. Biochem. Cell Biol. 2013, 45, 364–374. [Google Scholar] [CrossRef]
  22. Konig, J.; Wells, J.; Cani, P.D.; Garcia-Rodenas, C.L.; MacDonald, T.; Mercenier, A.; Whyte, J.; Troost, F.; Brummer, R.J. Human Intestinal Barrier Function in Health and Disease. Clin. Transl. Gastroenterol. 2016, 7, e196. [Google Scholar] [CrossRef] [PubMed]
  23. Ermund, A.; Schutte, A.; Johansson, M.E.; Gustafsson, J.K.; Hansson, G.C. Studies of mucus in mouse stomach, small intestine, and colon. I. Gastrointestinal mucus layers have different properties depending on location as well as over the Peyer’s patches. Am. J. Physiol. Gastrointest. Liver Physiol. 2013, 305, G341–G347. [Google Scholar] [CrossRef] [PubMed]
  24. Schutte, A.; Ermund, A.; Becker-Pauly, C.; Johansson, M.E.; Rodriguez-Pineiro, A.M.; Backhed, F.; Muller, S.; Lottaz, D.; Bond, J.S.; Hansson, G.C. Microbial-induced meprin beta cleavage in MUC2 mucin and a functional CFTR channel are required to release anchored small intestinal mucus. Proc. Natl. Acad. Sci. USA 2014, 111, 12396–12401. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Clevers, H.C.; Bevins, C.L. Paneth cells: Maestros of the small intestinal crypts. Annu. Rev. Physiol. 2013, 75, 289–311. [Google Scholar] [CrossRef] [PubMed]
  26. Propheter, D.C.; Chara, A.L.; Harris, T.A.; Ruhn, K.A.; Hooper, L.V. Resistin-like molecule beta is a bactericidal protein that promotes spatial segregation of the microbiota and the colonic epithelium. Proc. Natl. Acad. Sci. USA 2017, 114, 11027–11033. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Hedblom, G.A.; Reiland, H.A.; Sylte, M.J.; Johnson, T.J.; Baumler, D.J. Segmented Filamentous Bacteria-Metabolism Meets Immunity. Front Microbiol. 2018, 9, 1991. [Google Scholar] [CrossRef]
  28. Birchenough, G.M.; Johansson, M.E.; Gustafsson, J.K.; Bergstrom, J.H.; Hansson, G.C. New developments in goblet cell mucus secretion and function. Mucosal. Immunol. 2015, 8, 712–719. [Google Scholar] [CrossRef] [Green Version]
  29. Pelaseyed, T.; Bergstrom, J.H.; Gustafsson, J.K.; Ermund, A.; Birchenough, G.M.; Schutte, A.; van der Post, S.; Svensson, F.; Rodriguez-Pineiro, A.M.; Nystrom, E.E.; et al. The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system. Immunol. Rev. 2014, 260, 8–20. [Google Scholar] [CrossRef] [Green Version]
  30. Li, H.; Limenitakis, J.P.; Fuhrer, T.; Geuking, M.B.; Lawson, M.A.; Wyss, M.; Brugiroux, S.; Keller, I.; Macpherson, J.A.; Rupp, S.; et al. The outer mucus layer hosts a distinct intestinal microbial niche. Nat. Commun. 2015, 6, 8292. [Google Scholar] [CrossRef]
  31. Sommer, F.; Backhed, F. The gut microbiota--masters of host development and physiology. Nat. Rev. Microbiol. 2013, 11, 227–238. [Google Scholar] [CrossRef]
  32. Jakobsson, H.E.; Rodriguez-Pineiro, A.M.; Schutte, A.; Ermund, A.; Boysen, P.; Bemark, M.; Sommer, F.; Backhed, F.; Hansson, G.C.; Johansson, M.E. The composition of the gut microbiota shapes the colon mucus barrier. EMBO Rep. 2015, 16, 164–177. [Google Scholar] [CrossRef] [PubMed]
  33. Johansson, M.E.; Jakobsson, H.E.; Holmen-Larsson, J.; Schutte, A.; Ermund, A.; Rodriguez-Pineiro, A.M.; Arike, L.; Wising, C.; Svensson, F.; Backhed, F.; et al. Normalization of Host Intestinal Mucus Layers Requires Long-Term Microbial Colonization. Cell Host. Microbe 2015, 18, 582–592. [Google Scholar] [CrossRef] [Green Version]
  34. Song, M.; Xia, B.; Li, J. Effects of topical treatment of sodium butyrate and 5-aminosalicylic acid on expression of trefoil factor 3, interleukin 1beta, and nuclear factor kappaB in trinitrobenzene sulphonic acid induced colitis in rats. Postgrad. Med. J. 2006, 82, 130–135. [Google Scholar] [CrossRef] [Green Version]
  35. Finnie, I.A.; Dwarakanath, A.D.; Taylor, B.A.; Rhodes, J.M. Colonic mucin synthesis is increased by sodium butyrate. Gut 1995, 36, 93–99. [Google Scholar] [CrossRef] [Green Version]
  36. Gaudier, E.; Rival, M.; Buisine, M.P.; Robineau, I.; Hoebler, C. Butyrate enemas upregulate Muc genes expression but decrease adherent mucus thickness in mice colon. Physiol. Res. 2009, 58, 111–119. [Google Scholar] [CrossRef] [PubMed]
  37. Willemsen, L.E.; Koetsier, M.A.; van Deventer, S.J.; van Tol, E.A. Short chain fatty acids stimulate epithelial mucin 2 expression through differential effects on prostaglandin E(1) and E(2) production by intestinal myofibroblasts. Gut 2003, 52, 1442–1447. [Google Scholar] [CrossRef] [Green Version]
  38. Wlodarska, M.; Luo, C.; Kolde, R.; d’Hennezel, E.; Annand, J.W.; Heim, C.E.; Krastel, P.; Schmitt, E.K.; Omar, A.S.; Creasey, E.A.; et al. Indoleacrylic Acid Produced by Commensal Peptostreptococcus Species Suppresses Inflammation. Cell Host Microbe 2017, 22, 25–37.e6. [Google Scholar] [CrossRef] [Green Version]
  39. Yin, J.; Yang, K.; Zhou, C.; Xu, P.; Xiao, W.; Yang, H. Aryl hydrocarbon receptor activation alleviates dextran sodium sulfate-induced colitis through enhancing the differentiation of goblet cells. Biochem. Biophys Res. Commun. 2019, 514, 180–186. [Google Scholar] [CrossRef]
  40. Burger-van Paassen, N.; Vincent, A.; Puiman, P.J.; van der Sluis, M.; Bouma, J.; Boehm, G.; van Goudoever, J.B.; van Seuningen, I.; Renes, I.B. The regulation of intestinal mucin MUC2 expression by short-chain fatty acids: Implications for epithelial protection. Biochem. J. 2009, 420, 211–219. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  41. Wlodarska, M.; Thaiss, C.A.; Nowarski, R.; Henao-Mejia, J.; Zhang, J.P.; Brown, E.M.; Frankel, G.; Levy, M.; Katz, M.N.; Philbrick, W.M.; et al. NLRP6 inflammasome orchestrates the colonic host-microbial interface by regulating goblet cell mucus secretion. Cell 2014, 156, 1045–1059. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  42. Shuai, K.; Liu, B. Regulation of JAK-STAT signalling in the immune system. Nat. Rev. Immunol. 2003, 3, 900–911. [Google Scholar] [CrossRef]
  43. Boudny, V.; Kovarik, J. JAK/STAT signaling pathways and cancer. Janus kinases/signal transducers and activators of transcription. Neoplasma 2002, 49, 349–355. [Google Scholar]
  44. Jarry, A.; Merlin, D.; Velcich, A.; Hopfer, U.; Augenlicht, L.H.; Laboisse, C.L. Interferon-gamma modulates cAMP-induced mucin exocytosis without affecting mucin gene expression in a human colonic goblet cell line. Eur. J. Pharmacol. 1994, 267, 95–103. [Google Scholar] [CrossRef]
  45. Dharmani, P.; Srivastava, V.; Kissoon-Singh, V.; Chadee, K. Role of intestinal mucins in innate host defense mechanisms against pathogens. J. Innate. Immun. 2009, 1, 123–135. [Google Scholar] [CrossRef] [PubMed]
  46. Enss, M.L.; Cornberg, M.; Wagner, S.; Gebert, A.; Henrichs, M.; Eisenblatter, R.; Beil, W.; Kownatzki, R.; Hedrich, H.J. Proinflammatory cytokines trigger MUC gene expression and mucin release in the intestinal cancer cell line LS180. Inflamm. Res. 2000, 49, 162–169. [Google Scholar] [CrossRef]
  47. Thai, P.; Loukoianov, A.; Wachi, S.; Wu, R. Regulation of airway mucin gene expression. Annu. Rev. Physiol. 2008, 70, 405–429. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  48. Iwashita, J.; Sato, Y.; Sugaya, H.; Takahashi, N.; Sasaki, H.; Abe, T. mRNA of MUC2 is stimulated by IL-4, IL-13 or TNF-alpha through a mitogen-activated protein kinase pathway in human colon cancer cells. Immunol. Cell Biol. 2003, 81, 275–282. [Google Scholar] [CrossRef] [PubMed]
  49. Blanchard, C.; Durual, S.; Estienne, M.; Bouzakri, K.; Heim, M.H.; Blin, N.; Cuber, J.C. IL-4 and IL-13 up-regulate intestinal trefoil factor expression: Requirement for STAT6 and de novo protein synthesis. J. Immunol. 2004, 172, 3775–3783. [Google Scholar] [CrossRef] [Green Version]
  50. Kim, C.H.; Song, K.S.; Koo, J.S.; Kim, H.U.; Cho, J.Y.; Kim, H.J.; Yoon, J.H. IL-13 suppresses MUC5AC gene expression and mucin secretion in nasal epithelial cells. Acta Otolaryngol. 2002, 122, 638–643. [Google Scholar] [CrossRef]
  51. Jayawickreme, S.P.; Gray, T.; Nettesheim, P.; Eling, T. Regulation of 15-lipoxygenase expression and mucus secretion by IL-4 in human bronchial epithelial cells. Am. J. Physiol. 1999, 276, L596–L603. [Google Scholar] [CrossRef] [PubMed]
  52. Louahed, J.; Toda, M.; Jen, J.; Hamid, Q.; Renauld, J.C.; Levitt, R.C.; Nicolaides, N.C. Interleukin-9 upregulates mucus expression in the airways. Am. J. Respir. Cell Mol. Biol. 2000, 22, 649–656. [Google Scholar] [CrossRef] [Green Version]
  53. Hasnain, S.Z.; Tauro, S.; Das, I.; Tong, H.; Chen, A.C.; Jeffery, P.L.; McDonald, V.; Florin, T.H.; McGuckin, M.A. IL-10 promotes production of intestinal mucus by suppressing protein misfolding and endoplasmic reticulum stress in goblet cells. Gastroenterology 2013, 144, 357–368.e9. [Google Scholar] [CrossRef] [PubMed]
  54. Sugimoto, K.; Ogawa, A.; Mizoguchi, E.; Shimomura, Y.; Andoh, A.; Bhan, A.K.; Blumberg, R.S.; Xavier, R.J.; Mizoguchi, A. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J. Clin. Investig. 2008, 118, 534–544. [Google Scholar] [CrossRef] [Green Version]
  55. Volk, J.K.; Nystrom, E.E.L.; van der Post, S.; Abad, B.M.; Schroeder, B.O.; Johansson, A.; Svensson, F.; Javerfelt, S.; Johansson, M.E.V.; Hansson, G.C.; et al. The Nlrp6 inflammasome is not required for baseline colonic inner mucus layer formation or function. J. Exp. Med. 2019, 216, 2602–2618. [Google Scholar] [CrossRef]
  56. Levy, M.; Thaiss, C.A.; Zeevi, D.; Dohnalova, L.; Zilberman-Schapira, G.; Mahdi, J.A.; David, E.; Savidor, A.; Korem, T.; Herzig, Y.; et al. Microbiota-Modulated Metabolites Shape the Intestinal Microenvironment by Regulating NLRP6 Inflammasome Signaling. Cell 2015, 163, 1428–1443. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  57. Nowarski, R.; Jackson, R.; Gagliani, N.; de Zoete, M.R.; Palm, N.W.; Bailis, W.; Low, J.S.; Harman, C.C.; Graham, M.; Elinav, E.; et al. Epithelial IL-18 Equilibrium Controls Barrier Function in Colitis. Cell 2015, 163, 1444–1456. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  58. Jarret, A.; Jackson, R.; Duizer, C.; Healy, M.E.; Zhao, J.; Rone, J.M.; Bielecki, P.; Sefik, E.; Roulis, M.; Rice, T.; et al. Enteric Nervous System-Derived IL-18 Orchestrates Mucosal Barrier Immunity. Cell 2020, 180, 813–814. [Google Scholar] [CrossRef] [Green Version]
  59. Ramanan, D.; Tang, M.S.; Bowcutt, R.; Loke, P.; Cadwell, K. Bacterial sensor Nod2 prevents inflammation of the small intestine by restricting the expansion of the commensal Bacteroides vulgatus. Immunity 2014, 41, 311–324. [Google Scholar] [CrossRef] [Green Version]
  60. Sonnenburg, J.L.; Xu, J.; Leip, D.D.; Chen, C.H.; Westover, B.P.; Weatherford, J.; Buhler, J.D.; Gordon, J.I. Glycan foraging in vivo by an intestine-adapted bacterial symbiont. Science 2005, 307, 1955–1959. [Google Scholar] [CrossRef] [Green Version]
  61. Brownlee, I.A.; Havler, M.E.; Dettmar, P.W.; Allen, A.; Pearson, J.P. Colonic mucus: Secretion and turnover in relation to dietary fibre intake. Proc. Nutr. Soc. 2003, 62, 245–249. [Google Scholar] [CrossRef]
  62. Hedemann, M.S.; Theil, P.K.; Bach Knudsen, K.E. The thickness of the intestinal mucous layer in the colon of rats fed various sources of non-digestible carbohydrates is positively correlated with the pool of SCFA but negatively correlated with the proportion of butyric acid in digesta. Br. J. Nutr. 2009, 102, 117–125. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  63. Earle, K.A.; Billings, G.; Sigal, M.; Lichtman, J.S.; Hansson, G.C.; Elias, J.E.; Amieva, M.R.; Huang, K.C.; Sonnenburg, J.L. Quantitative Imaging of Gut Microbiota Spatial Organization. Cell Host Microbe 2015, 18, 478–488. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  64. Desai, M.S.; Seekatz, A.M.; Koropatkin, N.M.; Kamada, N.; Hickey, C.A.; Wolter, M.; Pudlo, N.A.; Kitamoto, S.; Terrapon, N.; Muller, A.; et al. A Dietary Fiber-Deprived Gut Microbiota Degrades the Colonic Mucus Barrier and Enhances Pathogen Susceptibility. Cell 2016, 167, 1339–1353.e21. [Google Scholar] [CrossRef] [Green Version]
  65. Schroeder, B.O.; Birchenough, G.M.H.; Stahlman, M.; Arike, L.; Johansson, M.E.V.; Hansson, G.C.; Backhed, F. Bifidobacteria or Fiber Protects against Diet-Induced Microbiota-Mediated Colonic Mucus Deterioration. Cell Host Microbe 2018, 23, 27–40.e7. [Google Scholar] [CrossRef] [Green Version]
  66. Rodriguez-Cabezas, M.E.; Camuesco, D.; Arribas, B.; Garrido-Mesa, N.; Comalada, M.; Bailon, E.; Cueto-Sola, M.; Utrilla, P.; Guerra-Hernandez, E.; Perez-Roca, C.; et al. The combination of fructooligosaccharides and resistant starch shows prebiotic additive effects in rats. Clin. Nutr. 2010, 29, 832–839. [Google Scholar] [CrossRef]
  67. Mastrodonato, M.; Calamita, G.; Mentino, D.; Scillitani, G. High-fat Diet Alters the Glycosylation Patterns of Duodenal Mucins in a Murine Model. J. Histochem. Cytochem. 2020, 68, 279–294. [Google Scholar] [CrossRef]
  68. Gulhane, M.; Murray, L.; Lourie, R.; Tong, H.; Sheng, Y.H.; Wang, R.; Kang, A.; Schreiber, V.; Wong, K.Y.; Magor, G.; et al. High Fat Diets Induce Colonic Epithelial Cell Stress and Inflammation that is Reversed by IL-22. Sci. Rep. 2016, 6, 28990. [Google Scholar] [CrossRef]
  69. Martinez-Medina, M.; Denizot, J.; Dreux, N.; Robin, F.; Billard, E.; Bonnet, R.; Darfeuille-Michaud, A.; Barnich, N. Western diet induces dysbiosis with increased E coli in CEABAC10 mice, alters host barrier function favouring AIEC colonisation. Gut 2014, 63, 116–124. [Google Scholar] [CrossRef] [PubMed]
  70. Agus, A.; Denizot, J.; Thevenot, J.; Martinez-Medina, M.; Massier, S.; Sauvanet, P.; Bernalier-Donadille, A.; Denis, S.; Hofman, P.; Bonnet, R.; et al. Western diet induces a shift in microbiota composition enhancing susceptibility to Adherent-Invasive E. coli infection and intestinal inflammation. Sci. Rep. 2016, 6, 19032. [Google Scholar] [CrossRef] [Green Version]
  71. Chassaing, B.; Koren, O.; Goodrich, J.K.; Poole, A.C.; Srinivasan, S.; Ley, R.E.; Gewirtz, A.T. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature 2015, 519, 92–96. [Google Scholar] [CrossRef] [Green Version]
  72. Laudisi, F.; Di Fusco, D.; Dinallo, V.; Stolfi, C.; Di Grazia, A.; Marafini, I.; Colantoni, A.; Ortenzi, A.; Alteri, C.; Guerrieri, F.; et al. The Food Additive Maltodextrin Promotes Endoplasmic Reticulum Stress-Driven Mucus Depletion and Exacerbates Intestinal Inflammation. Cell. Mol. Gastroenterol. Hepatol. 2019, 7, 457–473. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  73. Lan, A.; Andriamihaja, M.; Blouin, J.M.; Liu, X.; Descatoire, V.; Desclee de Maredsous, C.; Davila, A.M.; Walker, F.; Tome, D.; Blachier, F. High-protein diet differently modifies intestinal goblet cell characteristics and mucosal cytokine expression in ileum and colon. J. Nutr. Biochem. 2015, 26, 91–98. [Google Scholar] [CrossRef] [PubMed]
  74. Mu, C.; Yang, Y.; Luo, Z.; Guan, L.; Zhu, W. The Colonic Microbiome and Epithelial Transcriptome Are Altered in Rats Fed a High-Protein Diet Compared with a Normal-Protein Diet. J. Nutr. 2016, 146, 474–483. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  75. Mu, C.; Yang, Y.; Luo, Z.; Zhu, W. Temporal microbiota changes of high-protein diet intake in a rat model. Anaerobe 2017, 47, 218–225. [Google Scholar] [CrossRef]
  76. Beaumont, M.; Portune, K.J.; Steuer, N.; Lan, A.; Cerrudo, V.; Audebert, M.; Dumont, F.; Mancano, G.; Khodorova, N.; Andriamihaja, M.; et al. Quantity and source of dietary protein influence metabolite production by gut microbiota and rectal mucosa gene expression: A randomized, parallel, double-blind trial in overweight humans. Am. J. Clin. Nutr. 2017, 106, 1005–1019. [Google Scholar] [CrossRef] [Green Version]
  77. McNamara, N.; Basbaum, C. Signaling networks controlling mucin production in response to Gram-positive and Gram-negative bacteria. Glycoconj. J. 2001, 18, 715–722. [Google Scholar] [CrossRef]
  78. Dohrman, A.; Miyata, S.; Gallup, M.; Li, J.D.; Chapelin, C.; Coste, A.; Escudier, E.; Nadel, J.; Basbaum, C. Mucin gene (MUC 2 and MUC 5AC) upregulation by Gram-positive and Gram-negative bacteria. Biochim. Biophys. Acta 1998, 1406, 251–259. [Google Scholar] [CrossRef] [Green Version]
  79. Smirnova, M.G.; Guo, L.; Birchall, J.P.; Pearson, J.P. LPS up-regulates mucin and cytokine mRNA expression and stimulates mucin and cytokine secretion in goblet cells. Cell Immunol. 2003, 221, 42–49. [Google Scholar] [CrossRef]
  80. Engevik, M.A.; Luk, B.; Chang-Graham, A.L.; Hall, A.; Herrmann, B.; Ruan, W.; Endres, B.T.; Shi, Z.; Garey, K.W.; Hyser, J.M.; et al. Bifidobacterium dentium Fortifies the Intestinal Mucus Layer via Autophagy and Calcium Signaling Pathways. mBio 2019, 10, e01087-19. [Google Scholar] [CrossRef] [Green Version]
  81. Soderholm, A.T.; Pedicord, V.A. Intestinal epithelial cells: At the interface of the microbiota and mucosal immunity. Immunology 2019, 158, 267–280. [Google Scholar] [CrossRef] [Green Version]
  82. Martin, R.; Chamignon, C.; Mhedbi-Hajri, N.; Chain, F.; Derrien, M.; Escribano-Vazquez, U.; Garault, P.; Cotillard, A.; Pham, H.P.; Chervaux, C.; et al. The potential probiotic Lactobacillus rhamnosus CNCM I-3690 strain protects the intestinal barrier by stimulating both mucus production and cytoprotective response. Sci. Rep. 2019, 9, 5398. [Google Scholar] [CrossRef] [Green Version]
  83. Mattar, A.F.; Teitelbaum, D.H.; Drongowski, R.A.; Yongyi, F.; Harmon, C.M.; Coran, A.G. Probiotics up-regulate MUC-2 mucin gene expression in a Caco-2 cell-culture model. Pediatr. Surg. Int. 2002, 18, 586–590. [Google Scholar] [CrossRef] [PubMed]
  84. Caballero-Franco, C.; Keller, K.; De Simone, C.; Chadee, K. The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells. Am. J. Physiol. Gastrointest Liver Physiol. 2007, 292, G315–G322. [Google Scholar] [CrossRef]
  85. Lemjabbar, H.; Basbaum, C. Platelet-activating factor receptor and ADAM10 mediate responses to Staphylococcus aureus in epithelial cells. Nat. Med. 2002, 8, 41–46. [Google Scholar] [CrossRef] [PubMed]
  86. Byrd, J.C.; Yan, P.; Sternberg, L.; Yunker, C.K.; Scheiman, J.M.; Bresalier, R.S. Aberrant expression of gland-type gastric mucin in the surface epithelium of Helicobacter pylori-infected patients. Gastroenterology 1997, 113, 455–464. [Google Scholar] [CrossRef] [PubMed]
  87. Allen, A.; Newton, J.; Oliver, L.; Jordan, N.; Strugala, V.; Pearson, J.P.; Dettmar, P.W. Mucus and H. pylori. J. Physiol. Pharmacol. 1997, 48, 297–305. [Google Scholar] [PubMed]
  88. Slomiany, B.L.; Slomiany, A. Disruption in gastric mucin synthesis by Helicobacter pylori lipopolysaccharide involves ERK and p38 mitogen-activated protein kinase participation. Biochem. Biophys. Res. Commun. 2002, 294, 220–224. [Google Scholar] [CrossRef]
  89. Byrd, J.C.; Yunker, C.K.; Xu, Q.S.; Sternberg, L.R.; Bresalier, R.S. Inhibition of gastric mucin synthesis by Helicobacter pylori. Gastroenterology 2000, 118, 1072–1079. [Google Scholar] [CrossRef]
  90. Micots, I.; Augeron, C.; Laboisse, C.L.; Muzeau, F.; Megraud, F. Mucin exocytosis: A major target for Helicobacter pylori. J. Clin. Pathol. 1993, 46, 241–245. [Google Scholar] [CrossRef]
  91. Kelly, C.P.; Becker, S.; Linevsky, J.K.; Joshi, M.A.; O’Keane, J.C.; Dickey, B.F.; LaMont, J.T.; Pothoulakis, C. Neutrophil recruitment in Clostridium difficile toxin A enteritis in the rabbit. J. Clin. Investig. 1994, 93, 1257–1265. [Google Scholar] [CrossRef]
  92. Pothoulakis, C.; Sullivan, R.; Melnick, D.A.; Triadafilopoulos, G.; Gadenne, A.S.; Meshulam, T.; LaMont, J.T. Clostridium difficile toxin A stimulates intracellular calcium release and chemotactic response in human granulocytes. J. Clin. Investig. 1988, 81, 1741–1745. [Google Scholar] [CrossRef] [Green Version]
  93. Branka, J.E.; Vallette, G.; Jarry, A.; Bou-Hanna, C.; Lemarre, P.; Van, P.N.; Laboisse, C.L. Early functional effects of Clostridium difficile toxin A on human colonocytes. Gastroenterology 1997, 112, 1887–1894. [Google Scholar] [CrossRef]
  94. Henderson, I.R.; Czeczulin, J.; Eslava, C.; Noriega, F.; Nataro, J.P. Characterization of pic, a secreted protease of Shigella flexneri and enteroaggregative Escherichia coli. Infect. Immun. 1999, 67, 5587–5596. [Google Scholar] [CrossRef] [Green Version]
  95. Navarro-Garcia, F.; Gutierrez-Jimenez, J.; Garcia-Tovar, C.; Castro, L.A.; Salazar-Gonzalez, H.; Cordova, V. Pic, an autotransporter protein secreted by different pathogens in the Enterobacteriaceae family, is a potent mucus secretagogue. Infect. Immun. 2010, 78, 4101–4109. [Google Scholar] [CrossRef] [Green Version]
  96. Padra, M.; Adamczyk, B.; Flahou, B.; Erhardsson, M.; Chahal, G.; Smet, A.; Jin, C.; Thorell, A.; Ducatelle, R.; Haesebrouck, F.; et al. Helicobacter suis infection alters glycosylation and decreases the pathogen growth inhibiting effect and binding avidity of gastric mucins. Mucosal. Immunol. 2019, 12, 784–794. [Google Scholar] [CrossRef] [Green Version]
  97. Qadri, F.; Svennerholm, A.M.; Faruque, A.S.; Sack, R.B. Enterotoxigenic Escherichia coli in developing countries: Epidemiology, microbiology, clinical features, treatment, and prevention. Clin. Microbiol. Rev. 2005, 18, 465–483. [Google Scholar] [CrossRef] [Green Version]
  98. Kotloff, K.L.; Nataro, J.P.; Blackwelder, W.C.; Nasrin, D.; Farag, T.H.; Panchalingam, S.; Wu, Y.; Sow, S.O.; Sur, D.; Breiman, R.F.; et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): A prospective, case-control study. Lancet 2013, 382, 209–222. [Google Scholar] [CrossRef]
  99. Luo, Q.; Kumar, P.; Vickers, T.J.; Sheikh, A.; Lewis, W.G.; Rasko, D.A.; Sistrunk, J.; Fleckenstein, J.M. Enterotoxigenic Escherichia coli secretes a highly conserved mucin-degrading metalloprotease to effectively engage intestinal epithelial cells. Infect. Immun. 2014, 82, 509–521. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  100. Staff, P.P. Correction: SslE elicits functional antibodies that impair in vitro mucinase activity and in vivo colonization by both intestinal and extraintestinal Escherichia coli strains. PLoS Pathog. 2015, 11, e1004773. [Google Scholar] [CrossRef] [Green Version]
  101. Gerhardt, E.; Masso, M.; Paton, A.W.; Paton, J.C.; Zotta, E.; Ibarra, C. Inhibition of water absorption and selective damage to human colonic mucosa are induced by subtilase cytotoxin produced by Escherichia coli O113:H21. Infect. Immun. 2013, 81, 2931–2937. [Google Scholar] [CrossRef] [Green Version]
  102. Szabady, R.L.; Yanta, J.H.; Halladin, D.K.; Schofield, M.J.; Welch, R.A. TagA is a secreted protease of Vibrio cholerae that specifically cleaves mucin glycoproteins. Microbiology 2011, 157, 516–525. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  103. Mondal, M.; Nag, D.; Koley, H.; Saha, D.R.; Chatterjee, N.S. The Vibrio cholerae extracellular chitinase ChiA2 is important for survival and pathogenesis in the host intestine. PLoS ONE 2014, 9, e103119. [Google Scholar] [CrossRef] [Green Version]
  104. Bruchhaus, I.; Jacobs, T.; Leippe, M.; Tannich, E. Entamoeba histolytica and Entamoeba dispar: Differences in numbers and expression of cysteine proteinase genes. Mol. Microbiol. 1996, 22, 255–263. [Google Scholar] [CrossRef] [PubMed]
  105. Lidell, M.E.; Moncada, D.M.; Chadee, K.; Hansson, G.C. Entamoeba histolytica cysteine proteases cleave the MUC2 mucin in its C-terminal domain and dissolve the protective colonic mucus gel. Proc. Natl. Acad. Sci. USA 2006, 103, 9298–9303. [Google Scholar] [CrossRef] [Green Version]
  106. An, G.; Wei, B.; Xia, B.; McDaniel, J.M.; Ju, T.; Cummings, R.D.; Braun, J.; Xia, L. Increased susceptibility to colitis and colorectal tumors in mice lacking core 3-derived O-glycans. J. Exp. Med. 2007, 204, 1417–1429. [Google Scholar] [CrossRef]
  107. Dawson, P.A.; Huxley, S.; Gardiner, B.; Tran, T.; McAuley, J.L.; Grimmond, S.; McGuckin, M.A.; Markovich, D. Reduced mucin sulfonation and impaired intestinal barrier function in the hyposulfataemic NaS1 null mouse. Gut 2009, 58, 910–919. [Google Scholar] [CrossRef]
  108. Xavier, R.J.; Podolsky, D.K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007, 448, 427–434. [Google Scholar] [CrossRef]
  109. Mak, W.Y.; Zhao, M.; Ng, S.C.; Burisch, J. The epidemiology of inflammatory bowel disease: East meets west. J. Gastroenterol. Hepatol. 2020, 35, 380–389. [Google Scholar] [CrossRef]
  110. Sheng, Y.H.; Hasnain, S.Z.; Florin, T.H.; McGuckin, M.A. Mucins in inflammatory bowel diseases and colorectal cancer. J. Gastroenterol. Hepatol. 2012, 27, 28–38. [Google Scholar] [CrossRef]
  111. Heazlewood, C.K.; Cook, M.C.; Eri, R.; Price, G.R.; Tauro, S.B.; Taupin, D.; Thornton, D.J.; Png, C.W.; Crockford, T.L.; Cornall, R.J.; et al. Aberrant mucin assembly in mice causes endoplasmic reticulum stress and spontaneous inflammation resembling ulcerative colitis. PLoS Med. 2008, 5, e54. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  112. Moehle, C.; Ackermann, N.; Langmann, T.; Aslanidis, C.; Kel, A.; Kel-Margoulis, O.; Schmitz-Madry, A.; Zahn, A.; Stremmel, W.; Schmitz, G. Aberrant intestinal expression and allelic variants of mucin genes associated with inflammatory bowel disease. J. Mol. Med. 2006, 84, 1055–1066. [Google Scholar] [CrossRef] [PubMed]
  113. Barrett, J.C.; Hansoul, S.; Nicolae, D.L.; Cho, J.H.; Duerr, R.H.; Rioux, J.D.; Brant, S.R.; Silverberg, M.S.; Taylor, K.D.; Barmada, M.M.; et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat. Genet. 2008, 40, 955–962. [Google Scholar] [CrossRef] [Green Version]
  114. Pullan, R.D.; Thomas, G.A.; Rhodes, M.; Newcombe, R.G.; Williams, G.T.; Allen, A.; Rhodes, J. Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis. Gut 1994, 35, 353–359. [Google Scholar] [CrossRef] [Green Version]
  115. Strugala, V.; Dettmar, P.W.; Pearson, J.P. Thickness and continuity of the adherent colonic mucus barrier in active and quiescent ulcerative colitis and Crohn’s disease. Int. J. Clin. Pract. 2008, 62, 762–769. [Google Scholar] [CrossRef] [PubMed]
  116. Niv, Y. Mucin gene expression in the intestine of ulcerative colitis patients: A systematic review and meta-analysis. Eur. J. Gastroenterol. Hepatol. 2016, 28, 1241–1245. [Google Scholar] [CrossRef]
  117. Buisine, M.P.; Desreumaux, P.; Debailleul, V.; Gambiez, L.; Geboes, K.; Ectors, N.; Delescaut, M.P.; Degand, P.; Aubert, J.P.; Colombel, J.F.; et al. Abnormalities in mucin gene expression in Crohn’s disease. Inflamm. Bowel Dis. 1999, 5, 24–32. [Google Scholar] [CrossRef]
  118. Boltin, D.; Perets, T.T.; Vilkin, A.; Niv, Y. Mucin function in inflammatory bowel disease: An update. J. Clin. Gastroenterol. 2013, 47, 106–111. [Google Scholar] [CrossRef]
  119. Yamamoto-Furusho, J.K.; Mendivil, E.J.; Fonseca-Camarillo, G. Reduced expression of mucin 9 (MUC9) in patients with ulcerative colitis. Inflamm. Bowel Dis. 2012, 18, E601. [Google Scholar] [CrossRef]
  120. Yamamoto-Furusho, J.K.; Ascano-Gutierrez, I.; Furuzawa-Carballeda, J.; Fonseca-Camarillo, G. Differential Expression of MUC12, MUC16, and MUC20 in Patients with Active and Remission Ulcerative Colitis. Mediators. Inflamm. 2015, 2015, 659018. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  121. Larsson, J.M.; Karlsson, H.; Crespo, J.G.; Johansson, M.E.; Eklund, L.; Sjovall, H.; Hansson, G.C. Altered O-glycosylation profile of MUC2 mucin occurs in active ulcerative colitis and is associated with increased inflammation. Inflamm. Bowel Dis. 2011, 17, 2299–2307. [Google Scholar] [CrossRef]
  122. Bergstrom, K.S.; Kissoon-Singh, V.; Gibson, D.L.; Ma, C.; Montero, M.; Sham, H.P.; Ryz, N.; Huang, T.; Velcich, A.; Finlay, B.B.; et al. Muc2 protects against lethal infectious colitis by disassociating pathogenic and commensal bacteria from the colonic mucosa. PLoS Pathog. 2010, 6, e1000902. [Google Scholar] [CrossRef] [PubMed]
  123. Das, S.; Rachagani, S.; Sheinin, Y.; Smith, L.M.; Gurumurthy, C.B.; Roy, H.K.; Batra, S.K. Mice deficient in Muc4 are resistant to experimental colitis and colitis-associated colorectal cancer. Oncogene 2016, 35, 2645–2654. [Google Scholar] [CrossRef] [Green Version]
  124. Cornick, S.; Tawiah, A.; Chadee, K. Roles and regulation of the mucus barrier in the gut. Tissue Barriers 2015, 3, e982426. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  125. Park, S.W.; Zhen, G.; Verhaeghe, C.; Nakagami, Y.; Nguyenvu, L.T.; Barczak, A.J.; Killeen, N.; Erle, D.J. The protein disulfide isomerase AGR2 is essential for production of intestinal mucus. Proc. Natl. Acad. Sci. USA 2009, 106, 6950–6955. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  126. Wei, X.; Yang, Z.; Rey, F.E.; Ridaura, V.K.; Davidson, N.O.; Gordon, J.I.; Semenkovich, C.F. Fatty acid synthase modulates intestinal barrier function through palmitoylation of mucin 2. Cell Host Microbe 2012, 11, 140–152. [Google Scholar] [CrossRef] [Green Version]
  127. Iida, T.; Onodera, K.; Nakase, H. Role of autophagy in the pathogenesis of inflammatory bowel disease. World J. Gastroenterol. 2017, 23, 1944–1953. [Google Scholar] [CrossRef]
  128. Hooper, K.M.; Barlow, P.G.; Henderson, P.; Stevens, C. Interactions Between Autophagy and the Unfolded Protein Response: Implications for Inflammatory Bowel Disease. Inflamm. Bowel Dis. 2019, 25, 661–671. [Google Scholar] [CrossRef]
  129. Patel, K.K.; Miyoshi, H.; Beatty, W.L.; Head, R.D.; Malvin, N.P.; Cadwell, K.; Guan, J.L.; Saitoh, T.; Akira, S.; Seglen, P.O.; et al. Autophagy proteins control goblet cell function by potentiating reactive oxygen species production. EMBO J. 2013, 32, 3130–3144. [Google Scholar] [CrossRef] [Green Version]
Ijms 22 13642 g001 550
Figure 1. (A) Electron microscopy image taken from colonic murine section. (B) PAS Alcian Blue stained murine small intestine. Red circle indicates the mucin granules. (C) The intestinal stem cell differentiation into absorptive or secretory progenitor under the control of the Notch signaling. (Adapted from SERVIER MEDICAL ART (CC of license 3.0)).
Figure 1. (A) Electron microscopy image taken from colonic murine section. (B) PAS Alcian Blue stained murine small intestine. Red circle indicates the mucin granules. (C) The intestinal stem cell differentiation into absorptive or secretory progenitor under the control of the Notch signaling. (Adapted from SERVIER MEDICAL ART (CC of license 3.0)).
Ijms 22 13642 g001
Ijms 22 13642 g002 550
Figure 2. Differences between the small and large intestine. (Adapted from SERVIER MEDICAL ART (CC of license 3.0)).
Figure 2. Differences between the small and large intestine. (Adapted from SERVIER MEDICAL ART (CC of license 3.0)).
Ijms 22 13642 g002
Ijms 22 13642 g003 550
Figure 3. Mucin expression in response to type 1 and 2 cytokines. (Adapted from SERVIER MEDICAL ART (CC of license 3.0)).
Figure 3. Mucin expression in response to type 1 and 2 cytokines. (Adapted from SERVIER MEDICAL ART (CC of license 3.0)).
Ijms 22 13642 g003
Ijms 22 13642 g004 550
Figure 4. Goblet cells and the mucus layer in health and disease. (Adapted from SERVIER MEDICAL ART (CC of license 3.0)).
Figure 4. Goblet cells and the mucus layer in health and disease. (Adapted from SERVIER MEDICAL ART (CC of license 3.0)).
Ijms 22 13642 g004
Table
Table 1. Human mucins type.
Table 1. Human mucins type.
TypeGeneTissue Localization
SecretedMUC5ACStomach
MUC6Stomach, Brunner gland and duodenum
MUC2Jejunum and colon
MUC5BColon (weak expression)
MembraneMUC1Stomach, duodenum and colon
MUC3A/BSmall intestine and colon
MUC4Stomach and colon
MUC12Stomach, small intestine and colon
MUC13-15Small intestine and colon
MUC17Stomach, duodenum and colon
MUC20-21Colon
Table
Table 2. Modulation of mucin expression by bacterial components.
Table 2. Modulation of mucin expression by bacterial components.
SpeciesEffectorPathwayMucin Expression–Secretion
Pseudomonas aeruginosaFlagellinATP/Ca2+-ERK1/2↑ MUC2
Pseudomonas aeruginosaLPSMAPK-NF-κB↑ MUC2, MUC5AB, MUC5AC
Bifidobacterium dentium-Autophagy↑ MUC2 and other GCs products
Ruminococcus gnavus-Peptide-like factors↑ MUC2
Lactobacillus rhamnosus--↑ MUC2
Staphylococcus aureusLTAPAFR↑ MUC2
Helicobacter pyloriLPSPI3K/ERK MAPK↓ MUC5AC, MUC1, ↓ secretion
Clostridium difficileC. difficile toxin A?↓ secretion
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Melhem, H.; Regan-Komito, D.; Niess, J.H. Mucins Dynamics in Physiological and Pathological Conditions. Int. J. Mol. Sci. 2021, 22, 13642. https://doi.org/10.3390/ijms222413642

AMA Style

Melhem H, Regan-Komito D, Niess JH. Mucins Dynamics in Physiological and Pathological Conditions. International Journal of Molecular Sciences. 2021; 22(24):13642. https://doi.org/10.3390/ijms222413642

Chicago/Turabian Style

Melhem, Hassan, Daniel Regan-Komito, and Jan Hendrik Niess. 2021. "Mucins Dynamics in Physiological and Pathological Conditions" International Journal of Molecular Sciences 22, no. 24: 13642. https://doi.org/10.3390/ijms222413642

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop